Jiegeng Decoction Potentiates the Anticancer Efficacy of Paclitaxel in vivo and in vitro

Paclitaxel (PTX) has been the first-line treatment for lung cancer; however, its clinical use is limited due to multidrug resistance (MDR) and adverse effects. Thus, there is an urgent need to explore agents that can enhance the anticancer efficacy of PTX by reducing drug resistance and adverse reac...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Haifang, Li, Guofeng, Liu, Ye, Lang, Yifan, Yang, Wuliang, Zhang, Wugang, Liang, Xinli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914467/
https://www.ncbi.nlm.nih.gov/pubmed/35281908
http://dx.doi.org/10.3389/fphar.2022.827520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914467/
https://www.ncbi.nlm.nih.gov/pubmed/35281908
http://dx.doi.org/10.3389/fphar.2022.827520

Ejemplares similares